ACROBiosystems百普赛斯全面助力ADC药物研发，在原有的靶点蛋白业务基础上推出ADCC / ADCP功能验证报告基因细胞株以及过表达细胞株产品。其中，ADCC / ADCP功能验证报告基因细胞株覆盖全部已知FcγR基因型助力ADC药物Fc功能细胞水平评估，过表达细胞株基于成熟的细胞构建平台开发，可应用于ADC药物靶细胞杀伤验证，致力于为您提供更加全面的ADC药物质量表征解决方案！
抗体偶联药物（ADC）通过抗体（或抗体片段）与细胞毒性药物（Payload）通过连接子（Linker）形成的一种具有独特靶向性和高杀伤力的药物。部分ADC与肿瘤细胞表面抗原结合后内化进入细胞，在肿瘤细胞内释放细胞毒性药物，从而靶向杀伤肿瘤细胞。部分在胞内释放的细胞毒性药物被释放至肿瘤细胞外，通过旁观者效应进一步杀伤临近的肿瘤细胞。此外，ADC的抗体部分亦可以通过抑制靶抗原功能以及抗体介导的免疫反应等方式杀伤或抑制肿瘤细胞。
在ADC药物的研发过程中，抗原的选择和验证是基础。靶抗原作为ADC药物识别肿瘤细胞的关键，其特异性和表达水平直接影响药物的疗效。因此，在抗原选择时，需充分考虑其在肿瘤组织中的表达情况、与正常组织的差异以及是否易于抗体识别等因素。此外，针对肿瘤微环境中高表达的靶抗原也逐渐引起产业界关注，例如：肿瘤血管系统中的靶点、肿瘤细胞外基质中的靶点、肿瘤相关成纤维细胞有关靶点等。
在抗原选择和验证的基础上，进行抗体及ADC药物的筛选是研发的重要环节。理想的抗体应具有高亲和力、高效内化能力、低免疫原性，并能维持较长的血浆半衰期。IgG1抗体亚型因其较长的半衰期、较好的稳定性及能够诱导Fc介导的效应功能而受到青睐。通过体外实验，可以评估ADC药物对肿瘤细胞的杀伤效果、对正常细胞的毒性以及是否具备旁观者效应等。
为了深入研究ADC药物的作用机制并全面评价其功能，ACROBiosystems百普赛斯推出了ADC靶点蛋白过表达细胞系（Overexpression Stable Cell Lines）产品，这些细胞系通过基因工程手段，在宿主细胞膜表面长期稳定地表达特定抗原，为ADC药物的靶点特异性及亲和力验证、作用机制研究和体外药效评估提供了强有力的工具。
ADC药物的疗效不仅依赖于其携带的毒性Payload，还可利用Fc介导的效应功能实现对肿瘤细胞的杀伤和清除，例如抗体依赖性细胞介导的细胞毒作用(ADCC)、补体依赖性细胞毒作用(CDC) 和抗体依赖性细胞吞噬作用 (ADCP)。
在ADCC过程中，ADC药物的Fab端与靶细胞表面的抗原结合，同时其Fc部分与免疫效应细胞（如NK细胞）表面的FcγR结合，激活免疫效应细胞释放细胞毒性物质，从而杀死靶细胞。而在ADCP过程中，ADC药物的Fc部分与肿瘤相关巨噬细胞（TAM）表面的FcγR结合，激活巨噬细胞产生吞噬作用，将靶细胞吞噬并降解。因此，评估ADC药物的ADCC/ADCP效应对于确保药物的安全性和有效性至关重要。
Fc介导的效应功能
为了高效、准确地评估ADC药物的ADCC/ADCP效应，ACROBiosystems百普赛斯推出ADCC / ADCP功能验证报告基因细胞株。通过基因工程改造，在Jurkat细胞内转入一个受NFAT信号调控驱动的Luciferase报告基因，同时使其在细胞膜表面表达一种FcγR。当将该细胞与靶细胞和相关抗体共培养时，抗体同时结合靶细胞抗原和该细胞表面Fcγ受体，导致受体聚集、细胞内信号传导和NFAT介导的Luciferase 报告基因表达与发光。
-
• FcγR家族全覆盖，FcγRIIIa (158F/V)，FcγRIIa (131H/R) 、不同基因型可供选择；
-
• 选用Jurkat细胞构建，模拟真实免疫细胞状态；
-
• 采用荧光素酶(Luc)报告基因系统，反应信号强，检测窗口大，灵敏度高；
-
• 经代次稳定性验证，可稳定传代>20代，利于方法学验证；
-
• 经商业化抗体验证，应用场景明确；
-
• 售前免费样本测试，售后专业技术支持团队+无忧售后政策保障 ☛点击查看ACRO兜底售后政策；
-
• 为客户IND申报提供支持文件。
ADCC/ADCP功能验证细胞株原理图
FACS analysis of Nectin-4 on HEK293/Human Nectin-4 Stable Cell Line.
FACS assay shows that Anti-Nectin-4 antibody can bind to HEK293/Human Nectin-4 Stable Cell Line (Cat. No. CHEK-ATP035). HEK293/Human Nectin-4 stable cells was red line, Negative control HEK293 cells was grey line (QC tested).
FACS assay shows that Anti-TROP-2 antibody can bind to HEK293/Human TROP-2 Stable Cell Line.
HEK293/Human TROP-2 stable cells (Cat. No. CHEK-ATP036) was red line, Negative control HEK293 cells was grey line (QC tested).
Human CD16a (158V) (Luc) Jurkat Reporter Cell Development Service
(Cat.No. SCJUR-STF067)
ADCC response to anti-human CD20 antibody (RLU).
Anti-human CD20 antibody-induced ADCC activity was evaluated using Human CD16a (158V) (Luc) Jurkat Reporter Cell in the presence of Raji cells that express CD20 endogenously. The EC50 of anti-human CD20 antibody was approximately 0.0028 μg/mL.
ADCC response to anti-human CD20 antibody (FOLD).
Anti-human CD20 antibody-induced ADCC activity was evaluated using Human CD16a (158V) (Luc) Jurkat Reporter Cell in the presence of Raji cells that express CD20 endogenously. The max induction fold was approximately 854.
Human CD32a (131H) (Luc) Jurkat Reporter Cell Development Service
(Cat.No. SCJUR-STF069)
ADCP response to anti-human CD20 antibody (RLU).
Anti-human CD20 antibody-induced ADCP activity was evaluated using Human CD32a (131H) (Luc) Jurkat Reporter Cell in the presence of Raji cells that express CD20 endogenously. The EC50 was approximately 0.1054 μg/mL.
ADCP response to anti-human CD20 antibody (FOLD).
Anti-human CD20 antibody-induced ADCP activity was evaluated using Human CD32a (131H) (Luc) Jurkat Reporter Cell in the presence of Raji cells that express CD20 endogenously. The max induction fold was approximately 277.90.
Human CD16a (158V) (Luc) Jurkat Reporter Cell Development Service
(Cat.No. SCJUR-STF067)
Expression analysis of human CD16a (158V) on Human CD16a (158V) (Luc) Jurkat Reporter Cell by FACS.
Human CD16a (158V) (Luc) Jurkat Reporter Cell or negative control cell were stained with PE-labeled anti-human CD16a antibody.
Human CD32a (131H) (Luc) Jurkat Reporter Cell Development Service
(Cat.No. SCJUR-STF069)
Expression analysis of human CD32a on Human CD32a (131H) (Luc) Jurkat Reporter Cell by FACS.
Cell surface staining was performed on Human CD32a (131H) (Luc) Jurkat Reporter Cell or negative control cell using PE-labeled anti-human CD32a antibody.
Human CD16a (158V) (Luc) Jurkat Reporter Cell Development Service
(Cat.No. SCJUR-STF067)
Passage stability analysis by Signaling Bioassay.
The continuously growing Human CD16a (158V) (Luc) Jurkat Reporter Cell was stimulated with serial dilutions of anti-human CD20 antibody in the presence of Raji cells that express CD20 endogenously. Anti-human CD20 antibody stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 14-26.
Human CD32a (131H) (Luc) Jurkat Reporter Cell Development Service
(Cat.No. SCJUR-STF069)
Passage stability analysis by Signaling Bioassay.
The continuously growing Human CD32a (131H) (Luc) Jurkat Reporter Cell was stimulated with serial dilutions of Anti-human CD20 antibody in the presence of Raji cells. Anti-human CD20 antibody stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 10-23.
Star Ribbon预染蛋白Marker蛋白质标记物是生物研究和药物开发的重要组成部分。无论是用于蛋白质电泳还是western blot，我们的预染色蛋白质标记物帮助您快速确定目标蛋白质的分子量或评估转移效率。Fc受体蛋白治疗性抗体的功效取决于Fab片段及其对目标抗原的结合活性，还取决于Fc片段及其与关键Fc受体的相互作用。因此，在抗体工程中候选物必须针对一系列受体进行测试。探索我们的重组Fc受体蛋白质的全面收藏！
膜杰作
Star Staining
